The Two-century Journey of Parkinson Disease Research

Overview

Journal Nat Rev Neurosci

Specialty Neurology

Date 2017 Mar 18

PMID 28303016

Citations 147

Authors

Serge Przedborski

Affiliations

Soon will be listed here.

Abstract

Since the first formal description of Parkinson disease (PD) two centuries ago, our understanding of this common neurodegenerative disorder has expanded at all levels of description, from the delineation of its clinical phenotype to the identification of its neuropathological features, neurochemical processes and genetic factors. Along the way, findings have led to novel hypotheses about how the disease develops and progresses, challenging our understanding of how neurodegenerative disorders wreak havoc on human health. In this Timeline article, I recount the fascinating 200-year journey of PD research.

Citing Articles

CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson's disease models.

Leser F, Junyor F, Pagnoncelli I, Delgado A, Medeiros I, Nobrega A J Neuroinflammation. 2025; 22(1):31.

PMID: 39894839 PMC: 11789347. DOI: 10.1186/s12974-024-03318-x.

Alpha-synuclein Fibrils Inhibit Activation of the BDNF/ERK Signaling Loop in the mPFC to Induce Parkinson's Disease-like Alterations with Depression.

Ma Z, Xu Y, Lian P, Wu Y, Liu K, Zhang Z Neurosci Bull. 2024; .

PMID: 39609371 DOI: 10.1007/s12264-024-01323-x.

Manganese Exposure Enhances the Release of Misfolded α-Synuclein via Exosomes by Impairing Endosomal Trafficking and Protein Degradation Mechanisms.

Rokad D, Harischandra D, Samidurai M, Chang Y, Luo J, Lawana V Int J Mol Sci. 2024; 25(22).

PMID: 39596274 PMC: 11594990. DOI: 10.3390/ijms252212207.

Neuroprotective Effects of Ethanol Extract (EEPG) Against Glutamate Induced Neurotoxicity in HT22 Cells.

Nguyen Q, Yoo K, Pham T, Selvaraj B, Vu H, Le T Int J Mol Sci. 2024; 25(22).

PMID: 39596219 PMC: 11595212. DOI: 10.3390/ijms252212153.

Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier.

Cazalla E, Cuadrado A, Garcia-Yague A Fluids Barriers CNS. 2024; 21(1):93.

PMID: 39574123 PMC: 11580557. DOI: 10.1186/s12987-024-00599-5.

References

Burchell V, Nelson D, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt R, Pogson J . The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat Neurosci. 2013; 16(9):1257-65. PMC: 3827746. DOI: 10.1038/nn.3489. View

Mirza B, Hadberg H, Thomsen P, Moos T . The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience. 2000; 95(2):425-32. DOI: 10.1016/s0306-4522(99)00455-8. View

Geisler S, Holmstrom K, Skujat D, Fiesel F, Rothfuss O, Kahle P . PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010; 12(2):119-31. DOI: 10.1038/ncb2012. View

Wooten G, Currie L, Bennett J, Harrison M, Trugman J, Parker Jr W . Maternal inheritance in Parkinson's disease. Ann Neurol. 1997; 41(2):265-8. DOI: 10.1002/ana.410410218. View

Crossman A . Neural mechanisms in disorders of movement. Comp Biochem Physiol A Comp Physiol. 1989; 93(1):141-9. DOI: 10.1016/0300-9629(89)90201-6. View

Swerdlow R, Parks J, Davis 2nd J, Cassarino D, Trimmer P, Currie L . Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol. 1998; 44(6):873-81. DOI: 10.1002/ana.410440605. View

Heman-Ackah S, Hallegger M, Rao M, Wood M . RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis. Front Mol Neurosci. 2013; 6:40. PMC: 3834244. DOI: 10.3389/fnmol.2013.00040. View

Carlsson A, Lindqvist M, Magnusson T . 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957; 180(4596):1200. DOI: 10.1038/1801200a0. View

Rosin B, Slovik M, Mitelman R, Rivlin-Etzion M, Haber S, Israel Z . Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron. 2011; 72(2):370-84. DOI: 10.1016/j.neuron.2011.08.023. View

10.

Compston A . Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509. Brain. 2009; 132(Pt 8):1997-2001. DOI: 10.1093/brain/awp193. View

11.

Braak H, Braak E, Yilmazer D, Schultz C, de Vos R, Jansen E . Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl. 1995; 46:15-31. View

12.

Kravitz A, Freeze B, Parker P, Kay K, Thwin M, Deisseroth K . Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010; 466(7306):622-6. PMC: 3552484. DOI: 10.1038/nature09159. View

13.

Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A . Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet. 2016; 98(3):500-513. PMC: 4800038. DOI: 10.1016/j.ajhg.2016.01.014. View

14.

Walaas S, Aswad D, Greengard P . A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 1983; 301(5895):69-71. DOI: 10.1038/301069a0. View

15.

Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M . α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015; 522(7556):340-4. DOI: 10.1038/nature14547. View

16.

Hirsch E, Graybiel A, Agid Y . Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988; 334(6180):345-8. DOI: 10.1038/334345a0. View

17.

Hernan M, Takkouche B, Caamano-Isorna F, Gestal-Otero J . A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002; 52(3):276-84. DOI: 10.1002/ana.10277. View

18.

Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S . Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000; 25(3):302-5. DOI: 10.1038/77060. View

19.

Schapira A, Mann V, Cooper J, Dexter D, Daniel S, Jenner P . Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 1990; 55(6):2142-5. DOI: 10.1111/j.1471-4159.1990.tb05809.x. View

20.

Tecuapetla F, Jin X, Lima S, Costa R . Complementary Contributions of Striatal Projection Pathways to Action Initiation and Execution. Cell. 2016; 166(3):703-715. DOI: 10.1016/j.cell.2016.06.032. View